Glycemic control in the metabolic syndrome and implications in preventing cardiovascular disease

Metabolic Syndrome and Related Disorders

Volumn 4, Issue 4, 2006, Pages 315-327

  Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; INSULIN DERIVATIVE; INSULIN SENSITIZING AGENT; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ANXIETY; BLOOD PRESSURE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY CONSUMPTION; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; INSULIN RELEASE; INSULIN RESISTANCE; LACTIC ACIDOSIS; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; NAUSEA; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PULSE RATE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; XEROSTOMIA;

EID: 33846518864     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2006.4.315     Document Type: Review

References (116)

1. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004;27: 201-207.
2. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-240.
3. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163:1306-1316.
4. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141: 421-431.
5. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care 1999;22:920-924.
6. Khaw K-T, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322:15-18.
7. Woerle HJ, Pimenta W, Meyer C, Gosmanov N, Szoke E, Szombathy T, Mitrakou A, Gerich J. Diagnostic and therapeutic implications of relationships between fasting, 2 hour postchallenge plasma glucose and HbA1c values. Arch Intern Med 2004;164: 1627-1632.
8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-S36.
9. American College of Endocrinology. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002; 8(Suppl 1):5-11.
10. Standl E. International Diabetes Federation European Policy Group standards for diabetes. Endocr Pract 2002;8(Suppl 1):37-40.
11. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289.
12. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.
13. Knowler W, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E, Nathan D. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
14. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077.
15. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002;51:2796-2803.
16. Deng S, Vatamaniuk M, Huang X, Doliba N, Lian MM, Frank A, Velidedeoglu E, Desai NM, Koeberlein B, Wolf B, Barker CF, Naji A, Matschinsky FM, Markmann JF. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 2004;53:624-632.
17. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995;44:1249-1258.
18. Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Jarvinen H, Ferrannini E. Independent influence of age on basal insulin secretion in nondiabetic humans: European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab 1999;84:863-868.
19. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
20. DeFronzo R, Ferrannini E. Insulin resistance: A multifaceted syndrome response for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
21. American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998;21:310-314.
22. Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: Effects of troglitazone. Diabetologia 1998;41:569-576.
23. Cummings M, Watts G, Umpleby A, Hennessy T, Kelly J, Jackson N, Sönksen P. Acute hyperinsulinemia decreases the hepatic secretion of very-lowdensity lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995;44:1059-1065.
24. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
25. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005;26:650-661.
26. Church TS, Cheng YJ, Earnest CP, Barlow CE, Gibbons LW, Priest EL, Blair SN. Exercise capacity and body composition as predictors of mortality among men with diabetes. Diabetes Care 2004;27:83-88.
27. Rexrode KM, Carey VJ, Hennekens. CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843-1848.
28. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-2094.
29. Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab 2004;89:4206-4210.
30. Svendsen OL, Hassager C, Christiansen C. Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med 1993;95:131-140.
31. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005;65: 385-411.
32. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 2002;287:360-372.
33. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
34. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003;27:1437-1446.
35. DeRosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004;17:222-229.
36. Leung WY, Neil TG, Chan JC, Tomlinson B. Weight management and current options in pharmacotherapy: Orlistat and sibutramine. Clin Ther 2003;25: 58-80.
37. Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004;27: 1077-1080.
38. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004;27:33-40.
39. Despres JF, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
40. Franco OH, de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med 2005;165:2355-2360.
41. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe Study. Lancet 2005;363:1389-1397.
42. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat 2002;68-69:619-631.
43. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del A, I, Cippitelli A, Nava F, Piomelli D, Rodriguez DF. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-9617.
44. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100.
45. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Effect on glycemic control of exenaticle (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-2377.
46. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28: 1083-1091.
47. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab 2002;4:415-423.
48. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2002;25:1033-1041.
49. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: A meta-analysis of clinical studies. Diabetes Care 2005;28:942-949.
50. Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003;63:1879-1894.
51. Stumvoll M, Nurjhan N, Perrietto G, Dailey G, Gerich J. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554.
52. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-2069.
53. Cusi K, Consoli A, DeFronzo R. Metabolic effects of metformin on glucose and lactate metabolism in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-4067.
54. Hundal H, Ramlal T, Reyes R, Leiter L, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992;131:1165-1172.
55. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med 2004;256:1-14.
56. Seufert J, Lubben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther 2004;26:805-818.
57. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005;54:1566-1572.
58. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
59. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 2005;28:736-744.
60. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005;28:539-543.
61. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163: 2594-2602.
62. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338: 265-266.
63. Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, Shulman G. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-872.
64. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142: 611-619.
65. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;6:283-296.
66. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
67. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
68. Lebovitz HE, Banerji MA. Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol 2004;490: 135-146.
69. Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097-2104.
70. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941-2948.
71. Chiasson J, Josse R, Hunt J, Palmason C, Rodger N, Ross S, Ryan E, Tan M, Wolever T. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial. Ann Intern Med 1994;121: 928-935.
72. Chiasson JL, josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003;290:486-494.
73. Smith T, Gerich JE. Insulin secretogogues. In: Fonseca V, ed. Clinical Diabetes. Philadelphia: Elsevier Science, 2006:293-304.
74. Gerich J. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-1245.
75. Culy CR, Jarvis B. Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001;61:1625-1660.
76. Dunn C, Faulds D. Nateglinide. Drugs 2000;60: 607-615.
77. Langtry H, Balfour J. Glimepiride: A review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-584.
78. Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 2003;46(Suppl 1):M37-M43.
79. ATP channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000;293:444-452.
80. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: Mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003;17:11-15.
81. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607-1611.
82. Simonson D, Ferrannini E, Bevilacqua S, Smith D, Barrett E, Carlson R, DeFronzo R. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984;33:838-845.
83. Schade D, Jovanovic L, Schneider J, A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38: 636-641.
84. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM. Repaglinide versus nateglinide monotherapy: A randomized, multicenter study. Diabetes Care 2004;27:1265-1270.
85. Jawa AA, Fonseca VA. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. Cardiol Clin 2005;23:119-138.
86. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-2940.
87. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: Evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004;286:E882-E890.
88. Sinclair EM, Drucker DJ. Proglucagon-derived peptides: Mechanisms of action and therapeutic potential. Physiology (Bethesda) 2005;20:357-365.
89. List JF, Habener JF. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells. Am J Physiol Endocrinol Metab 2004;286:E875-E881.
90. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004;47:478-487.
91. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004;53:2181-2189.
92. Vilsboll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357-366.
93. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287:E199-E206.
94. Sinclair EM, Drucker DJ. Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: New therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabet 2005;12:146-151.
95. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: Augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145-5148.
96. Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5149-5158.
97. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
98. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003;12:87-100.
99. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2874-2880.
100. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002;137:25-33.
101. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29:6S44-6S52.
102. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29:6S95-6S103.
103. Mamputu JC, Wiernsperger NF, Renier C. Antiatherogenic properties of metformin: The experimental evidence. Diabetes Metab 2003;29:6S71-6S76.
104. Pavlovic D, Kocic R, Kocic G, Jevtovic T, Radenkovic S, Mikic D, Stojanovic M, Djordjevic PB. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab 2000;2:251-256.
105. Faure P, Rossini E, Wiernsperger N, Richard MJ, Favier A, Halimi S. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999;48:353-357.
106. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab 1999;25: 110-127.
107. Bailey C, Turner R. Metformin. N Engl J Med 1996; 334:574-579.
108. Standeven KF, Ariens RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethyl-biguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002;51:189-197.
109. Sirtori CR, Franceschini G, Gianfranceschi G, Sirtori M, Montanari G, Bosisio E, Mantero E, Bondioli A. Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 1984;6:914-923.
110. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: More than just a complication. Diabetes Metab 2003;29:6S77-6S87.
111. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-1350.
112. Bestermann W, Houston MC, Basile J, Egan B, Ferrario CM, Lackland D, Hawkins RG, Reed J, Rogers P, Wise D, Moore MA. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States. II. Treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005;329:292-305.
113. Parulkar A, Pendergrass M, Granda-Ayala R, Lee T, Fonseca V. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
114. Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: Effects of oral antidiabetic agents. Am J Cardiovasc Drugs 2005; 5:201-209.
115. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol 2003;92:50J-60J.
116. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-2084.